Stockscreener 앱 받기
29.61
6.10%
-1.95
전일 마감가:
$31.56
열려 있는:
$31.65
하루 거래량:
5.95M
Relative Volume:
1.75
시가총액:
$4.29B
수익:
$62.38M
순이익/손실:
$-101.59M
주가수익비율:
-34.25
EPS:
-0.8644
순현금흐름:
$-139.93M
1주 성능:
+38.03%
1개월 성능:
+28.74%
6개월 성능:
+223.17%
1년 성능:
+562.98%
1일 변동 폭
$29.42
$31.66
1주일 범위
$19.43
$32.79
52주 변동 폭
$4.3216
$32.79
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
29.69 | 4.57B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
437.09 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.41 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.63 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.25 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data - Investing.com
Tango Therapeutics stock hits all-time high at 32.69 USD - Investing.com India
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year - Yahoo Finance
Tango Therapeutics prices $600 million stock offering - Investing.com India
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Tango Therapeutics prices $600 million stock offering By Investing.com - Investing.com UK
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - GlobeNewswire
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Tango Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX) - Seeking Alpha
Tango Therapeutics stock rockets 53% on pancreatic cancer data - grafa.com
TNGX Maintained by HC Wainwright & Co. -- Price Target Raised to $66 - GuruFocus
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $42 - GuruFocus
Tango Therapeutics stock surges on pancreatic cancer trial data - qz.com
Tango Therapeutics stock hits all-time high at 32.69 USD By Investing.com - Investing.com South Africa
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Barchart
Canaccord raises Tango Therapeutics stock price target on drug combo By Investing.com - Investing.com Nigeria
Canaccord raises Tango Therapeutics stock price target on drug combo - Investing.com
B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating - marketscreener.com
Tango Therapeutics Stock Soars 53% After Pancreatic Cancer Trial Stuns Wall Street - TIKR.com
Tango Therapeutics launches $500M common stock offering - scanx.trade
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are - Benzinga
Tango Therapeutics stock soars on promising pancreatic cancer data - CryptoRank
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’ - MSN
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer - biocentury.com
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside - TradingView
Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant - Stock Titan
Tango Therapeutics (TNGX) director awarded RSUs and 25,000 stock options - Stock Titan
Tango Therapeutics (TNGX) director awarded 4,000 RSUs and 25,000 options - Stock Titan
Tango Therapeutics (TNGX) grants RSUs and stock options to director - Stock Titan
Tango Therapeutics files for $500 million common stock offering - MSN
TNGX Stock Whipsaws As Wall Street Hikes Price Targets - timothysykes.com
Clinical footwork pays off in Tango’s PDAC combo phase I/II - BioWorld News
Tango Therapeutics stock falls on $500M stock offering By Investing.com - Investing.com South Africa
Tango Therapeutics (TNGX) Sees Significant Stock Surge - GuruFocus
Tango Therapeutics stock soars 53% after 'unprecedented' data on pancreatic cancer treatment - MSN
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic CancerSlideshow (NASDAQ:TNGX) 2026-06-08 - Seeking Alpha
Tango Therapeutics (TNGX) launches $500M common stock offering with $75M overallotment - Stock Titan
Tango Therapeutics launches $500 million stock offering - Investing.com
Tango Therapeutics stock falls on $500M stock offering - Investing.com UK
Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Tango Therapeutics’ pancreatic cancer drug combo shows promise in study - whbl.com
TNGX: Vopimetostat plus pan-RAS inhibitors achieved a 92% response rate in MTAP-deleted pancreatic cancer - TradingView
Wolfe Research upgrades Tango Therapeutics stock rating on trial data By Investing.com - Investing.com Nigeria
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tango Therapeutics Inc 주식 (TNGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Jun 01 '26 |
Sale |
22.87 |
27,000 |
617,571 |
115,743 |
| Crystal Adam | President, R&D |
May 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
May 01 '26 |
Sale |
21.23 |
27,000 |
573,097 |
115,743 |
0.45%
0.07%
자본화:
|
볼륨(24시간):